Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy Announced April 2, 2024
Enrollment Initiated in 12-Patient Expansion Cohort of Voruciclib + Venetoclax in Ongoing Ph 1 Study April 2, 2024
Progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia reported April 2, 2024
ARYA-3 Clinical Trial Advances to Ph 2 for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS T-cell Therapy March 26, 2024
First patient dosed in Ph 1b/2 trial of LB-100 + dostarlimab-gxly in ovarian clear cell carcinoma March 26, 2024
Enrollment Completed for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with R/R PCNSL March 26, 2024
Lacutamab monotherapy development in PTCL to be discontinued after the anti-KIR3DL2 antibody fell short in Ph Ib trial March 26, 2024
Patient Recruitment completed for the Ph 2a Trial of MaaT013 + Immune Checkpoint Inhibitors in Metastatic Melanoma March 12, 2024
Debio0123 Monotherapy trial expanded In Gynecological Cancers And Other Biomarker-Driven Solid Tumors March 12, 2024
DURIPANC Ph 1b/2 clinical trial of Ampligen with Imfinzi for the treatment of pancreatic cancer opened for enrollment and enrolled first subject March 4, 2024
Patients Enrolling in Ph 1/2 Clinical Trial of IMNN-001 + Avastin in Advanced Ovarian Cancer March 4, 2024
Pivotal Ph 3 Trial of Trilaciclib to continue in metastatic TNBC Following Interim Analysis by IDMC February 26, 2024
First Patient dosed in the RIVER-52 Ph 2 Study of RVU120 for the Treatment of Patients with R/R AML and HR-MDS February 26, 2024
First Refractory Gastric Cancer Patient Dosed in Ph 2 Trial with Allogeneic INKT Cell Therapy and Botensilimab and Balstilimab February 26, 2024
First Patient Dosed in ALETA-001 Ph 1/2 Trial in Patients with R/R B-Cell Malignancies February 26, 2024
